Veranova

Activities: Manufacturing Ingredients

Trending Articles

  1. FDA approves AstraZeneca's FASENRA for hypereosinophilic syndrome AstraZeneca's FASENRA has received FDA approval for hypereosinophilic syndrome in adults and adolescents aged 12 and above, based on Phase III NATRON trial data showing a 65%...
  2. MHRA approves every-four-week dosing regimen for Chiesi's Elfabrio in stable adult Fabry disease patients The firm has received MHRA approval for an additional 2 mg/kg every-four-week dosing regimen for pegunigalsidase alfa, halving the number of annual infusions required for...
  3. FDA issues first cGMP warning letter citing AI misuse in pharmaceutical manufacturing A Michigan-based lab has become the subject of the FDA's first dedicated enforcement action on artificial intelligence misuse in drug manufacturing — a landmark event with...
  4. embecta completes £100m acquisition of UK-based Owen Mumford to bolster drug delivery portfolio US diabetes care company embecta has finalised its acquisition of Owen Mumford, gaining access to the Aidaptus next-generation auto-injector platform as it accelerates its...
  5. You need to be a subscriber to read this article.
    Click here to find out more.
    Wearable pumps and subcutaneous delivery: a new frontier in heart failure management Two recent developments are reshaping how drug delivery technology can move treatment out of the clinic and into patients’ everyday lives — with implications for both...

Upcoming event

CHEMUK 2026

20–21 May 2026 | Conference and Exhibition | Birmingham, UK See all

Related Content

Manufacturing

Veranova appoints Chief Quality Officer

Jacquelyn Martin will assume global leadership of Veranova’s Quality and Regulatory functions, supporting the company’s continued drive for excellence in quality and compliance and growth in advanced pharmaceutical modalities
Regulatory

Veranova’s Devens site passes FDA inspection with zero observations

This result demonstrates Veranova’s commitment to driving the highest standards of quality and compliance, and delivering consistent and reliable product supply for customers and patients

Veranova appoints Thomas Rohrer as vice president of bioconjugation

Industry veteran to lead expanding cGMP capabilities for ADC and bioconjugate development
Manufacturing

Veranova appoints Dr. Matteo Villain as Vice President of Peptides and Oligonucleotides

Dr. Villain will bring extensive expertise in peptide and oligonucleotide development and manufacturing to Veranova as the company continues to strengthen its position as a key player in the Peptide and Oligonucleotide (TIDES) space
Manufacturing

Veranova announces cGMP bioconjugation expansion in Devens

$50 million investment to support ADC manufacturing and create 70 new jobs
Manufacturing

Veranova appoints Elizabeth Rebeil as Global Vice President

Veranova appoints Elizabeth Rebeil as Global Vice President of Supply Chain and Operational Excellence
Manufacturing

Veranova to expand US ADC and API capabilities with $30m investment

The extension of the Devens, Massachusetts site will allow Veranova to serve the growing demand of ADC manufacturing in the US
Subscribe now